KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Tax Provisions (2016 - 2025)

Pacira BioSciences has reported Tax Provisions over the past 13 years, most recently at -$1.1 million for Q4 2025.

  • Quarterly results put Tax Provisions at -$1.1 million for Q4 2025, down 111.24% from a year ago — trailing twelve months through Dec 2025 was $9.8 million (down 73.01% YoY), and the annual figure for FY2025 was $9.8 million, down 73.01%.
  • Tax Provisions for Q4 2025 was -$1.1 million at Pacira BioSciences, down from $4.1 million in the prior quarter.
  • Over the last five years, Tax Provisions for PCRX hit a ceiling of $17.7 million in Q2 2024 and a floor of -$8.0 million in Q4 2022.
  • Median Tax Provisions over the past 5 years was $4.0 million (2025), compared with a mean of $3.9 million.
  • Biggest five-year swings in Tax Provisions: soared 15735.71% in 2021 and later crashed 1588.84% in 2023.
  • Pacira BioSciences' Tax Provisions stood at -$1.1 million in 2021, then plummeted by 645.88% to -$8.0 million in 2022, then surged by 211.1% to $8.8 million in 2023, then grew by 7.18% to $9.5 million in 2024, then crashed by 111.24% to -$1.1 million in 2025.
  • The last three reported values for Tax Provisions were -$1.1 million (Q4 2025), $4.1 million (Q3 2025), and $2.9 million (Q2 2025) per Business Quant data.